Cell-free DNA sequencing
Sequencing of fragmentary cell-free DNA from blood — prenatal screening, minimal-residual-disease surveillance and therapy-selection liquid biopsy, pushed by error-corrected counting at ever-deeper limits of detection. The table carries two vendors with fully sourced dossier ledgers; the wider field awaits ledger-grade records.
1 · What it gives
Cell-free DNA sequencing reads the small fragments of DNA that dying cells shed into the bloodstream, turning a blood draw into a molecular sample of the tumors, the placenta or the transplant that shed them. The technology stacks three hard problems: recovering short (~140–170 bp) fragments at parts-per-thousand concentration against a vast wild-type background; building libraries from picogram inputs without letting preparation errors masquerade as variants; and suppressing sequencing noise with molecular barcodes and unique-molecule counting so that a signal hiding at one-in-a-million frequency survives the read. What began as prenatal trisomy screening has become three markets in one — non-invasive prenatal testing, minimal-residual-disease surveillance after treatment, and therapy-selection liquid biopsy — and each new market pushes the limit of detection another order of magnitude deeper. The regulatory record in the corpus shows how far that has gone: one vendor holds EU IVDR Class C certification across multiple cancers while another holds the first FDA approval for a liquid biopsy in non-small-cell lung cancer, and both run laboratory networks at clinical-throughput scale.
Key directions of cell-free DNA sequencing:
- Minimal-residual-disease surveillance (MRD Monitoring): tumor-informed and tumor-naive panels tracking recurrence months before imaging; Natera’s Signatera holds EU IVDR Class C certification across multiple cancers plus FDA companion-diagnostic approval in muscle-invasive bladder cancer and a PMDA approval in Japan for colorectal cancer.
- Therapy-selection liquid biopsy (Therapy Selection): comprehensive genomic profiling from plasma — Guardant Health’s Guardant360 CDx has been FDA-approved since 2020, with a May 2026 approval for the Liquid CDx generation.
- Multi-cancer screening (Early Detection): blood tests that look for signal before symptoms — Guardant’s Shield test received FDA clearance in 2024 as the screening frontier of the cfDNA market.
- Prenatal and donor-derived sampling (NIPT and Beyond): the original application — counting chromosome-scale aneuploidy from placental cfDNA — remains the volume base of the sequencing pipeline.
Sectoral value chain#
[blood draw] ──> [plasma separation] ──> [cfDNA extraction]
│
(picogram library input)
▼
[clinical report] <── [variant calling/reporting] <── [error-corrected sequencing]
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Blood collection | cfDNA-stabilizing tubes and logistics | In: patient blood. Out: plasma with preserved fragment landscape. |
| Plasma separation | centrifugation within the stability window | In: whole blood. Out: cell-free plasma. |
| cfDNA extraction | silica/magnetic purification of short fragments | In: plasma. Out: picogram-to-nanogram cfDNA. |
| Library preparation | end repair, adapters, molecular barcodes | In: cfDNA. Out: sequencing-ready indexed libraries. |
| Error-corrected sequencing | deep sequencing with unique-molecule counting | In: libraries. Out: variant calls at 0.01–0.1% allele frequency. |
| Reporting and CDx linkage | clinical interpretation, therapy linkage | In: calls. Out: MRD, screening or therapy-selection reports. |
Cross-cutting technologies of the sector:
- Molecular barcoding (UMI Error Correction): unique molecular identifiers that let the pipeline separate true variants from sequencing noise.
- Tumor-informed panel design (Patient-Specific Panels): bespoke assays built from each patient’s tumor genotype for maximal MRD sensitivity.
- Companion-diagnostic regulatory chains (CDx Co-approvals): drug–diagnostic co-approval packages that tie cfDNA assays to specific therapies.
2 · What it replaces 2 · matched by industry
| D2E4 | Crop disease forecasting models, spore traps, pheromone and smart pest traps and field diagnostics — spray when risk is real instead of calendar-based fungicide and insecticide programmes Replaces: Fixed-interval ("calendar") protective fungicide sprays and routine insecticide applications regardless of pest pressure | EAC |
| D2E– | On-farm culture, PCR panels, rapid tests and veterinary laboratory services for livestock and aquaculture — treat what is diagnosed instead of blanket and prophylactic antibiotic treatment Replaces: Blanket treatment of every clinical mastitis case, group metaphylaxis on suspicion, prophylactic antibiotics in hatcheries and ponds, … | DIAG |
3 · How to implement 6 steps
- 1Stabilized blood drawBlood is drawn into cfDNA-preserving tubes, fixing the fragment landscape against cell lysis during transport to the laboratory.
- 2Plasma separationPurification & downstreamDouble centrifugation within the stability window separates plasma from cells, because a single lysed leukocyte can swamp a tumor’s cfDNA signal.Who can do this step matched automatically✓ GMP industrial scale“testing, including mass spectrometry and analytical high performance liquid chromatography”“Lyophilized PCR kit for detection of Eimeria species.”
- 3Extraction and library preparationExtractionFormulation & blendingShort-fragment-optimized purification recovers picogram cfDNA, and adapters with molecular barcodes convert it into pooled, indexed libraries.Who can do this step matched automaticallySyAqua Group Thailand“vannamei genetics (broodstock, nauplii, and post-larvae) built on genomic selection/marker-assisted selection plus quantitative genetics (BLUP), with disease resistance screening …”India Glycols (NSE) India✓ GMP 7,500 MT/ industrial scale“ Novel technologies, including super critical technology for nutraceuticals where carbon dioxide is used as a green solvent during extraction processes.”NAAFCO Group Bangladesh“Core products include NPKS/organic compost fertilizers, pesticides (formulated/repacked in-house), and seed varieties (F1 hybrids and contract-grown rice/HYVs), plus a cGMP …”MIAVIT GmbH Germany125.000 tons“The young company started producing premixes for the feed industry.”
- 4Error-corrected sequencingTesting & analyticsDeep sequencing runs with unique-molecule counting; consensus rules push the reliable detection threshold down to allele fractions ordinary panels cannot see.Who can do this step matched automaticallyVaxxinova Norway Norwayindustrial scale“Vaxxinova develops, produces and markets a wide range of innovative vaccines and diagnostic services to protect livestock and fish against diseases.”✓ GMP industrial scale“ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”Rovita GmbH Germany“As an accredited laboratory, our partner Focus Foodlabs offers extensive services in the field of food analysis and food safety.”Agrosava Serbia“Since 2014, the seed quality testing laboratory has been accredited in accordance with SRPS ISO/IES 17025:2006 for the methods of sampling and testing seeds of cereals, industrial …”
- 5Variant callingBioinformatics pipelines apply tumor-informed or tumor-naive models, converting counted molecules into recurrence, screening or therapy-selection calls.
- 6Clinical reportingBoarded interpretation links calls to therapy decisions under the CLIA/CAP/IVDR regime, closing the loop from blood draw to treatment choice.
4 · Who delivers
Matched suppliers (matched automatically)
| AGC Biologics | United States | Producer | active |
| MGI (BGI Group) | China | Producer | active |
| Paris Biofoundry (France) | France | Research / RTO | active |
| eversyn GmbH | Germany | Producer | active |
| Simple Planet | South Korea | Producer | active |
| Cell AgriTech | Malaysia | Research / RTO | active |
| CellMEAT | South Korea | Producer | active |
| Novartis | Switzerland | Producer | active |
| AstraZeneca | United Kingdom | Producer | active |
| Lonza Group | Switzerland | Producer | active |
| Tsingke Biotechnology | China | Producer | active |
| Cryoport Systems | United States | Producer | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Natera | 🇺🇸 USA | Signatera MRD, Panorama NIPT | Tumor-informed MRD; IVDR Class C; FDA CDx; PMDA approval; $2.31 bn 2025 revenue | Commercial |
| Guardant Health | 🇺🇸 USA | Guardant360 CDx, Liquid CDx, Shield | First FDA-approved liquid biopsy for NSCLC; CLIA/CAP labs; $982 m 2025 revenue | Commercial |
5 · Rules & route to market
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
The US is both the technology center and the reimbursement battleground — FDA approvals and Medicare coverage decisions set the pace for the whole field.
First FDA liquid-biopsy approvals, MRD guideline traction, national lab networks#
- Guardant360 approvals: FDA approval of Guardant360 CDx in 2020 as the blood-based companion diagnostic for non-small-cell lung cancer, the Liquid CDx generation in May 2026, and the Shield screening test in 2024.
- Signatera’s regulatory stack: FDA companion-diagnostic approval in muscle-invasive bladder cancer, EU IVDR Class C certification across multiple cancers, and a PMDA approval in Japan — one assay carrying three regulatories.
- Clinical laboratory scale: Natera’s Austin expansion is designed to create the world’s largest sequencing capacity and up to 400 new jobs, on top of laboratories in Austin, San Carlos and Boulder (Colorado).
European Union
Europe’s role is the IVDR: the 2017/746 regulation’s Class C requirements are the strictest evidentiary bar the sector faces, and the certifications now appearing against it are the market passports.
IVDR Class C certification, pharmacopoeial-era quality, PMDA-EU reciprocity#
- Signatera under IVDR: EU Class C certification across multiple cancer types — the first corpus-grounded example of an MRD assay clearing Europe’s post-2022 device regime.
- Laboratory licensure map: CLIA and CAP accreditation plus state licensure in New York and California shape US throughput, while European labs face national accreditation under the same ISO 15189 spine.
- Japan as reciprocal market: PMDA approval for Signatera in colorectal cancer shows the MRD regulatory template already replicating beyond the US-EU axis.
China
China runs a parallel cfDNA market at national scale, with NMPA pathways for prenatal screening and oncology panels and home-grown sequencing champions — the corpus’s dossier coverage there is still ledger-thin, so this section carries market structure rather than vendor claims.
NMPA oncology panels, prenatal screening volume, domestic sequencing platforms#
- NMPA tumor-panel pathway: Chinese liquid-biopsy panels clear the NMPA route separately from prenatal licenses, and oncology NGS leaders are submitting early-screening panels for colorectal cancer.
- Prenatal screening at population scale: NIPT volume made China one of the largest cfDNA markets by draw count before oncology arrived.
- Domestic platforms: Chinese sequencers supply the domestic cfDNA pipeline, decoupling it from US instrument exports.
6 · Money: tenders & grants
| Grant | Development of cell-free protein synthesis platforms for discovery and/or production of biologicals European Commission · EU | Apr 13, 2027 141 days |
7 · Tech stack & innovations
The stack is a noise war: every stage exists to keep preparation and sequencing errors from impersonating biology.
- Stabilized collection and extraction (Blood-to-Library Front End):
- cfDNA-stabilizing tubes hold the fragment landscape for days, protecting the ~140–170 bp tumor-derived fraction from dilution by genomic DNA.
- case: high-throughput extraction feeding Natera’s Austin expansion — designed to be the world’s largest sequencing capacity.
- Molecular-barcoded libraries (UMI Counting):
- unique molecular identifiers tag each original fragment, so consensus collapsing can distinguish a one-in-a-million variant from a sequencing error.
- case: tumor-informed Signatera panels tracking recurrence across multiple cancers under IVDR Class C certification.
- Multi-cancer and screening assays (Population-Scale cfDNA):
- screening moves the technology from patients to populations, demanding specificity at population scale.
- case: Guardant’s Shield blood test, FDA-cleared in 2024, with laboratory capacity investment accelerating through 2026 to match volume.
Sources 2 · 0 independent · 2 producer sites
Producers' own sites 2
- investor.natera.com · investor.natera.com · investor.natera.com · www.natera.com · www.natera.com · www.natera.com · www.natera.com · www.sec.gov producer checked 2026-09-18
- investors.guardanthealth.com · investors.guardanthealth.com · investors.guardanthealth.com · investors.guardanthealth.com · www.businesswire.com · www.medicaldevice-network.com · www.sdbj.com · www.sec.gov producer checked 2026-09-18